CoChat

GLP-1 Agonists in Type 1 Diabetes Mellitus

Open access
Janzen, Kristin M., Steuber, Taylor D., Nisly, Sarah A. · 2016 · Annals of Pharmacotherapy
Cited by 53

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like peptide 1 (GLP-1) agonists, incretin, liraglutide, exenatide, albiglutide, dulaglutide, type 1 diabetes mellitus. Study Selection and Data Extraction: All English-language trials that examined glycemic end points using GLP-1 agonists in humans with T1DM were included. Data Synthesis: A total of 9 clinical trials examining the use of GLP-1 agonists in T1DM were identified. On average, hemoglobin A 1C (A1C) was lower than baseline, with a maximal lowering of 0.6%. This effect was not significant when tested against a control group, with a relative decrease in A1C of 0.1% to 0.2%. In all trials examined, reported hypoglycemia was low, demonstrating no difference when compared with insulin monotherapy. Weight loss was seen in all trials, with a maximum weight loss of 6.4 kg over 24 weeks. Gastrointestinal adverse effects are potentially limiting, with a significant number of patients in trials reporting nausea. Conclusion: The use of GLP-1 agonists should be considered in T1DM patients who are overweight or obese and not at glycemic goals despite aggressive insulin therapy; however, tolerability of these agents is a potential concern. Liraglutide has the strongest evidence for use and would be the agent of choice for use in overweight or obese adult patients with uncontrolled T1DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1060028016651279

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 26

  1. 10.1056/NEJM199309303291401 · DOI · Paper page
  2. 10.1016/j.clim.2013.04.006 · DOI
  3. 10.2337/dc16-S005 · DOI · Paper page
  4. 10.2310/JIM.0b013e318279b7d6 · DOI · Paper page
  5. 10.1111/j.1463-1326.2006.00599.x · DOI
  6. 10.1371/journal.pone.0137525 · DOI · Paper page
  7. 10.1111/j.1464-5491.2011.03331.x · DOI · Paper page
  8. 10.1371/journal.pone.0141085 · DOI · Paper page
  9. 10.1177/0897190014549837 · DOI
  10. 10.1016/j.diabres.2013.01.020 · DOI
  11. 10.2337/dc09-1959 · DOI · Paper page
  12. 10.1007/s00592-015-0800-6 · DOI
  13. 10.1177/1932296814542153 · DOI · Paper page
  14. 10.2337/dc13-1169 · DOI · Paper page
  15. 10.1016/j.jcjd.2013.10.006 · DOI · Paper page
  16. 10.1016/S2213-8587(15)00436-2 · DOI · Paper page
  17. 10.2337/dc11-0096 · DOI · Paper page
  18. 10.1530/EJE-11-0330 · DOI · Paper page
  19. 10.4158/EP13065.OR · DOI
  20. Exenatide, 2016, Red Book Online [database online]
  21. Liraglutide, 2015, Red Book Online [database online]
  22. 10.1007/s40261-016-0389-8 · DOI
  23. 10.1111/dom.12386 · DOI · Paper page
  24. 10.1111/j.1365-2125.2008.03221.x · DOI · Paper page
  25. 10.2337/dc08-1309 · DOI · Paper page
  26. 10.2337/dc15-1025 · DOI · Paper page

Cited by

See all 53

Metadata

Authors
Janzen, K. M., Steuber, T. D., & Nisly, S. A.
Venue
Annals of Pharmacotherapy
Published
2016-06-01
Volume
50
Issue
8
Pages
656-665
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2418981277
Cited by
53
References
12
FWCI
5.20
Type
journal article
Language
en
Open access
green
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 Agonists in Type 1 Diabetes Mellitus. https://app.cochat.ai/papers/10.1177/1060028016651279
The paper
Janzen, K. M., Steuber, T. D., & Nisly, S. A. (2016). GLP-1 Agonists in Type 1 Diabetes Mellitus. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028016651279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.